Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of daratumumab plus CyBorD versus CyBorD alone in newly diagnosed AL amyloidosis
MOH_2018-03-26_002269Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of daratumumab in light-chain amyloidosis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Hematologic complete response rate. Started Jan 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on MOH_2018-03-26_002269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-26_002269.